Kyle Doherty

Sac-TMT plus pembrolizumab has earned breakthrough therapy designation in China in frontline EGFR- and ALK-negative PD-L1+ NSCLC.

Sacituzumab govitecan displayed efficacy in terms of PFS both with/without pembrolizumab in patients with untreated TNBC.

Cassie Kline, MD, MAS, discusses data from the phase 2 FIREFLY-1 trial of tovorafenib in relapsed/refractory pediatric low-grade glioma.

David G. Pfister, MD, developed a combined modality organ preservation treatment program that shifted the landscape of head and neck cancers.

Heather McArthur, MD, MPH, FASCO, elaborates on clinical trial data for palazestrant monotherapy in breast cancers.

Balazs Halmos, MD, MS, and Jamie E. Chaft, MD, discuss how safety considerations contribute to treatment selection in NSCLC.

The FDA has granted breakthrough therapy designation to JSKN003 in HER2+ platinum-resistant ovarian cancer.

In the BARCODE1 screening study, prostate cancer testing by polygenic risk score identified a higher percentage than PSA testing or MRI.

Experts convened during an OncLive Scientific Interchange and Workshop to discuss the evolving treatment landscapes in CSCC and melanoma.

Tafasitamab plus lenalidomide and rituximab has been approved by the European Commission in relapsed/refractory follicular lymphoma.

Eniluracil plus capecitabine showed signs of improved efficacy vs capecitabine alone while maintaining safety in advanced/metastatic breast cancer.

Ciforadenant in combination with ipilimumab and nivolumab was safe and feasible but did not enhance activity in frontline ccRCC.

R. Lor Randall, MD, FACS, discusses findings from a phase 2 study of denosumab in patients with osteosarcoma.

The FDA has expanded the indications of 2 assays to identify patients with HER2+ breast cancer for treatment with T-DXd.

Revumenib displayed responses irrespective of disease subtype in relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

Alpelisib plus fulvestrant improved PFS vs fulvestrant alone in PIK3CA-mutated, hormone receptor–positive/HER2-negative advanced breast cancer.

The FDA has accepted and granted priority review to the sBLA for nivolumab plus AVD in untreated adult and pediatric classical Hodgkin lymphoma.

Belzutifan maintained efficacy benefits vs everolimus among patients with ccRCC after at least 2 prior VEGFR TKIs.

Abemaciclib monotherapy displayed a clinical benefit in some patients with HR+/HER2– breast cancer after CDK4/6 inhibitor therapy.

AJ1-11095 received orphan drug designation from the FDA in myelofibrosis.

Sonrotoclax monotherapy led to an ORR of 52.4% and a CR rate of 15.5% in relapsed/refractory MCL.

The FDA has granted breakthrough therapy designation to INCA033989 in CALR-mutated essential thrombocythemia.

Zanubrutinib displayed long-term PFS and responses in patients with relapsed/refractory CLL/SLL.

Zanubrutinib plus R-CHOP produced a high ORR and CR rate in untreated DLBCL with certain gene expression.

Intravesical cretostimogene grenadenorepvec was efficacious and safe in high-risk BCG-naive non–muscle-invasive bladder cancer.

Peripheral neuropathy was linked with improved efficacy outcomes after treatment with first-line enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

Ahead of the 2025 ASH Annual Meeting, OncLive spoke with experts in CLL care to preview the most anticipated meeting abstracts.

Health care providers and allied health care professionals found the gemcitabine intravesical system straightforward to use and safe in NMIBC.

PLN-101095 in combination with pembrolizumab led to responses in patients with ICI-refractory advanced solid tumors.

Fuzuloparib extended PFS vs placebo regardless of the addition of apatinib in newly diagnosed advanced ovarian cancer.